BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17848947)

  • 1. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
    Suttie SA; Park KG; Smith TA
    Br J Cancer; 2007 Oct; 97(7):902-9. PubMed ID: 17848947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
    Sharma RI; Smith TA
    J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
    Cooper AC; Fleming IN; Phyu SM; Smith TA
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro.
    Smith TA; Sharma RI; Wang WG; Welch AE; Schweiger LF; Collie-Duguid ES
    Nucl Med Biol; 2007 Nov; 34(8):955-60. PubMed ID: 17998098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
    Dittmann H; Dohmen BM; Kehlbach R; Bartusek G; Pritzkow M; Sarbia M; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1462-9. PubMed ID: 12397465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
    Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
    Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
    J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
    Law AA; Collie-Duguid ES; Smith TA
    Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
    Strickland AH; Karapetis CS; Yip D; Harper PG
    Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer.
    Couper GW; McAteer D; Wallis F; Norton M; Welch A; Nicolson M; Park KG
    Br J Surg; 1998 Oct; 85(10):1403-6. PubMed ID: 9782025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
    Highley MS; Parnis FX; Trotter GA; Houston SJ; Penson RT; Harper PG; Mason RC
    Br J Surg; 1994 Dec; 81(12):1763-5. PubMed ID: 7530150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.
    Ott K; Fink U; Becker K; Stahl A; Dittler HJ; Busch R; Stein H; Lordick F; Link T; Schwaiger M; Siewert JR; Weber WA
    J Clin Oncol; 2003 Dec; 21(24):4604-10. PubMed ID: 14673049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
    Yao Z; Guo H; Yuan Y; Zhao Y; Yao S; Xu Y; Liu L; Liu T; Liu Y; Yang S
    J Chemother; 2014 Apr; 26(2):117-21. PubMed ID: 24090813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
    Kilickap S; Yalcin S; Ates O; Tekuzman G
    Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
    Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.